Kenneth Finkelstein, DO
Urogynecology and Reconstructive Pelvic Surgery · Mokena, ILNPI 1245222165
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,866 of the $10,324 with a category attached, or 76.2%. 47 manufacturers reported payments, led by Medtronic at 34.8% of the total. Reporting peaked in 2023 at $2,574 and has fallen 63.4% since, to $942 in 2025.
Across 252 payments — averaging $40.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Caldera Medical, Inc$1K
- AbbVie$657
- Astellas Pharma US Inc$628
- Baxter Healthcare$619
- Olympus America Inc.$431
- plus $3K from 41 others
Across 75 payments — averaging $5328.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$170K
- Novavax Inc$112K
- Abbott$92K
- Pfizer$23K
- Imbrium Therapeutics L.p.$2K
Across 4 payments — averaging $62,500 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$250K
What the payments were for
- Consulting fees$5055%
- Travel & lodging$1,51515%
- Food & beverage$7,86676%
- Education$200%
- Other$4184%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,591
- Desara$1,108
- TISSEEL$505
- Olympus$418
- Vertessa$413
- SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM$261
- Anovo Surgical System$134
- Uterine Manipulators & Injectors$128
- StimSite$120
- Mara Console$106
How this compares
$10,324 in reported general payments places this provider in the 80th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
See all urogynecology and reconstructive pelvic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 106 | $63,546 |
| ElmironPentosan Polysulfate Sodium | 15 | $34,485 |
| Mirabegron ErMirabegron | 11 | $7,434 |
| GemtesaVibegron | 16 | $6,996 |
| Oxybutynin Chloride ErOxybutynin Chloride | 297 | $5,085 |
| Estradiol | 119 | $3,897 |
| Trospium Chloride ErTrospium Chloride | 21 | $3,092 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 14 | $1,151 |
| Solifenacin Succinate | 41 | $945 |
| Clobetasol Propionate | 33 | $939 |
| ValacyclovirValacyclovir Hcl | 21 | $432 |
| Ibuprofen | 61 | $213 |
| Misoprostol | 21 | $64 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $628 | $63,546106 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $53 | $6,99616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
Other urogynecology and reconstructive pelvic surgery in Mokena
- Abraham ShashouaChicago$339K
- Peter SandSkokie$185K
- Akira GillinghamChicago$58K
- Roger GoldbergSkokie$54K
- Kimberly KentonChicago$43K
- Traci BeckChicago$32K
- Raja ChatterjiSouth Elgin$30K
- Margaret MuellerChicago$26K
- Lisa JohnsonOak Lawn$24K
- Henry ChillEvanston$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.